StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities research analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 9.0 %

EVOK stock opened at $4.71 on Friday. The stock has a market capitalization of $7.02 million, a PE ratio of -0.43 and a beta of 0.16. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $15.13. The firm has a 50 day moving average of $5.01 and a 200 day moving average of $5.34.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.